Outlook Therapeutics (OTLK) Hits New 1-Year Low at $1.50

Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares reached a new 52-week low on Thursday . The stock traded as low as $1.50 and last traded at $1.56, with a volume of 1066925 shares trading hands. The stock had previously closed at $1.73.

Separately, ValuEngine raised Outlook Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, March 20th.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Thursday, February 14th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($2.48) by $1.68. The business had revenue of $1.07 million for the quarter.

COPYRIGHT VIOLATION WARNING: This news story was originally published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.wkrb13.com/2019/04/11/outlook-therapeutics-otlk-hits-new-1-year-low-at-1-50.html.

Outlook Therapeutics Company Profile (NASDAQ:OTLK)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Featured Article: What are the components of an earnings report?

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.